The Challenges of Treating Triple-negative Breast Cancer
A panel at the 2016 San Antonio Breast Cancer Symposium discussed the state of research and treatment of triple negative breast cancer (TNBC).
San Antonio Breast Cancer Symposium (SABCS)
Extending Adjuvant Anastrozole to 6 Years After Tamoxifen Does Not Improve Breast Cancer Survival
Extending adjuvant anastrozole therapy from 3 to 6 years after up to 3 years of tamoxifen does not improve breast cancer survival outcomes.
No Breast Cancer Survival Benefit for Extending Adjuvant Letrozole Therapy to 5 Years
Extending adjuvant letrozole from 2.5 to 5 years does not improve disease-free survival or overall survival outcomes among women with breast cancer.
Promising Options Emerging for Treating Metastatic ER+ Breast Cancer
Integration of newer targeted agents into combination therapies will necessitate the development of predictive biomarkers.
Everolimus Improves Fulvestrant Benefits in AI-Resistant Metastatic Breast Cancer
Adding everolimus to fulvestrant improves progression-free survival (PFS) among postmenopausal women.
The Current State of HER2+ Breast Cancer Management
Many agents are in ongoing trials, and may provide additional options for patients with metastatic HER2-positive disease.
Treating Older Patients With Breast Cancer: Still a Challenge
Lack of research data and failure to consider patients’ functional age affects how older adults with breast cancer are managed.
Clinically Important Factors Identified for Trastuzumab Response in HER2-positive Patients
Genetics, RNA subtype, and tumor microenvironment are clinically important and independently predictive of trastuzumab response.
Breast Cancers With PIK3CA Mutations May Derive Greater Benefit From Letrozole
Postmenopausal women with ER-positive, HER2-negative breast cancer with PIK3CA mutations may derive greater benefit from letrozole.
Novel BRD4 Inhibitor Enhances Endocrine Therapy Efficacy in ER+ Breast Cancer Models
The novel bromodomain-containing protein 4 (BRD4) inhibitor GS-6510 demonstrated anti-tumor activity.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in SABCS 2016
Loading... 
Loading...